Kenvue Inc. (NYSE:KVUE) Shares Sold by Wellington Management Group LLP

Wellington Management Group LLP trimmed its position in Kenvue Inc. (NYSE:KVUE) by 13.6% in the fourth quarter, Holdings Channel reports. The firm owned 68,363,434 shares of the company’s stock after selling 10,724,038 shares during the quarter. Wellington Management Group LLP’s holdings in Kenvue were worth $1,459,559,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Alerus Financial NA raised its position in shares of Kenvue by 0.3% during the 3rd quarter. Alerus Financial NA now owns 191,345 shares of the company’s stock valued at $4,426,000 after acquiring an additional 491 shares in the last quarter. Kiley Juergens Wealth Management LLC lifted its holdings in Kenvue by 1.9% in the fourth quarter. Kiley Juergens Wealth Management LLC now owns 27,110 shares of the company’s stock worth $579,000 after acquiring an additional 500 shares during the last quarter. Principle Wealth Partners LLC lifted its holdings in Kenvue by 3.7% in the fourth quarter. Principle Wealth Partners LLC now owns 14,194 shares of the company’s stock worth $303,000 after acquiring an additional 500 shares during the last quarter. White Pine Capital LLC boosted its stake in Kenvue by 1.0% in the fourth quarter. White Pine Capital LLC now owns 54,572 shares of the company’s stock valued at $1,165,000 after acquiring an additional 542 shares during the period. Finally, Deseret Mutual Benefit Administrators raised its position in shares of Kenvue by 29.0% during the 4th quarter. Deseret Mutual Benefit Administrators now owns 2,528 shares of the company’s stock worth $54,000 after purchasing an additional 568 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Stock Up 1.0 %

KVUE opened at $23.74 on Monday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The company has a market capitalization of $45.36 billion, a PE ratio of 44.78, a P/E/G ratio of 2.62 and a beta of 1.25. The stock’s fifty day moving average is $22.32 and its 200-day moving average is $22.45. Kenvue Inc. has a one year low of $17.67 and a one year high of $24.46.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Thursday, February 6th. The company reported $0.26 EPS for the quarter, hitting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. On average, equities analysts predict that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th were paid a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a yield of 3.45%. The ex-dividend date of this dividend was Wednesday, February 12th. Kenvue’s dividend payout ratio is presently 154.72%.

Analyst Upgrades and Downgrades

KVUE has been the subject of a number of analyst reports. Piper Sandler boosted their price objective on Kenvue from $24.00 to $27.00 and gave the company an “overweight” rating in a research report on Monday, February 24th. Canaccord Genuity Group boosted their price target on shares of Kenvue from $24.00 to $29.00 and gave the company a “buy” rating in a report on Wednesday, March 5th. Citigroup dropped their price objective on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a report on Wednesday, January 15th. Barclays boosted their target price on shares of Kenvue from $21.00 to $23.00 and gave the company an “equal weight” rating in a research note on Thursday. Finally, Evercore ISI started coverage on shares of Kenvue in a research note on Monday, March 24th. They issued an “in-line” rating and a $25.00 price target on the stock. One research analyst has rated the stock with a sell rating, eight have given a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $24.00.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.